冠心病介入治疗进展

冠心病介入治疗进展 - 2008,Safety of DESRevascularization: CABG or PCI Treatment for bifurcation: sample is better?Fractional flow-reserve for guidingNew generation of DES,Kirtane AJ, Stone GW. Comprehensive meta-analysis of DES vs BMS randomized trials and registries; March 28, 2008; Chicago, IL.,MEGA meta-analysis,a. Fixed-effects modelb. Random-effects model,All-cause mortality,Kirtane AJ, Stone GW. Comprehensive meta-analysis of DES vs BMS randomized trials and registries; March 28, 2008; Chicago, IL.,MI,a. Fixed-effects modelb. Random-effects model,MEGA meta-analysis,Kirtane AJ, Stone GW. Comprehensive meta-analysis of DES vs BMS randomized trials and registries; March 28, 2008; Chicago, IL.,Target-vessel revascularization,*Random-effects model,MEGA meta-analysis,Safety of DES Revascularization: CABG or PCITreatment for bifurcation: sample is better?Fractional flow-reserve for guiding PCI in multi-vessel diseaseNew generation of DES,The safety and effectiveness of the *TAXUS Express2 Stent System have not been established in the following patient populations: patients with vessel thrombus at the lesion site; patients with coronary artery lesions longer than 28 mm or requiring more than one TAXUS Stent; lesions located in the unprotected left main coronary artery, or lesions located at a bifurcation/trifurcation; patients with moderate or severe calcification in the lesion or a chronic total occlusion; or patients with multi-vessel disease. The TAXUS Express Stent System has not been specifically indicated for patients with diabetes.,SYNTAX (SYNergy between PCI with TAXUS* and cardiac surgery),Patient Profiling,Local Heart team (surgeon & interventional cardiologist) assessed each patient in regards to:Patients operative risk (EuroSCORE & Parsonnet score)Coronary lesion complexity (newly developed SYNTAX score)The goal of the SYNTAX score is to provide a tool to assist physicians in their revascularization strategies for patients with high risk lesions,Sianos et al, EuroIntervention 2005;1:219-227Valgimigli et al, Am J Cardiol 2007;99:1072-1081Serruys et al, EuroIntervention 2007;3:450-459Coronary tree segments based on the classification proposed by the AHA and modified for the ARTS study Circulation 1975; 51:31-3 4:209-19,Leaman score, Circ 1981;63:285-299Lesions classification ACC/AHA , Circ 2001;103:3019-3041Bifurcation classification, CCI 2000;49:274-283CTO classification, J Am Coll Cardiol 1997;30:649-656,Tortuosity,Thrombus,Bifurcation,Total Occlusion,3 Vessel,Left Main,Dominance,Calcification,Number & location of lesions,23 US Sites,62 EU Sites,+,SYNTAX Trial Design,Adverse Events to 12 Months,ITT population,Event Rate 1.5 SE, *Fisher exact test,All Death,Revascularization,CVA (Stroke),Myocardial Infarction,TAXUS* (N=903),CABG (N=897),MACCE to 12 Months,P=0.0015*,ITT population,12.1%,17.8%,Event Rate 1.5 SE. *Fishers Exact Test,Symptomatic Graft Occlusion & Stent Thrombosis to 12 Months,MACCE to 12 MonthsLeft Main Subset,P=0.44*,13.6%,15.8%,Event rate 1.5 SE, *Fisher exact test,ITT population,P=0.19*,7.7%,13.0%,Event rate 1.5 SE, *Fisher exact test,Calculated by core laboratory; ITT population,MACCE to 12 Months by SYNTAX Score TertileLow Scores (0-22) LM Subset,P=0.008*,25.3%,12.9%,Event rate 1.5 SE, *Fisher exact test,Calculated by core laboratory; ITT population,MACCE to 12 Months by SYNTAX Score TertileHigh Scores (33) Left Main Subset,Overall MACCE at 12 MonthsLeft Main Subset,ITT population,(n=705),(n=91),(n=138),(n=218),(n=258),P=0.44,P=1.0,P=0.27,P=0.29,P=0.42,Patients (%),MACCE to 12 Months 3VD Subset,P0.001*,19.1%,11.2%,ITT population,Event Rate 1.5 SE, *Fisher exact test,MACCE Components 3VD to 30 Days,P=0.08*,30 Day Event Rate, %,P=0.03*,P=0.02*,P=0.20,TAXUS* (n=546),CABG (n=549),P=0.45*,*chi-square test; Fisher exact test,CABG,TAXUS*,P=0.39,3 Vessel Disease*,n=34,n=43,*per protocol and ITT populations had same outcome,Combined Safety (Death/CVA/MI) 3VD,Patients (%),MACCE to 12 Months vs SYNTAX Score,SYNTAX Score22,P=0.10,Ptype Aif any of these applies, the operator may Stage 2 Kissing bolloon, T-stent, culotte stent, crush,PRIMARY ENDPOINTComposite (9months) Death, MI, TVF,In-hospital MACCE,CONCLUSIONS,For unselected bifurcation lesions, a stepwise provisional T stent trategy is superior to a systematic dual tenting strategy in all domains:procedural successprocedural complicationsin-hospital and 9-month MACE,Safety of DES Revascularization: CABG or PCITreatment for bifurcation: sample is better?Fractional flow-reserve for guiding PCI in multi-vessel diseaseNew generation of DES,FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY FOR GUIDING PCI IN PATIENTS WITH MULTIVESSEL CORONARY ARTERY DISEASE,FAME,Angiography-guided PCI,FFR-guided PCI,Measure FFR in all indicated stenoses,Stent all indicated stenoses,Stent only those stenoses with FFR 0.80,Randomization,Indicate all stenoses 50% considered for stenting,Patient with stenoses 50% in at least 2 of the 3 major epicardial vessels,1-year follow-up,FLOW CHART,FAME study: Procedural Results,30 days2.9%,90 days3.8%,180 days4.9%,360 days5.3%,Angio-guided,absolute difference in MACE-free survival,FAME study: Event-free Survival,Adverse Events at 1 year,Routine measurement of FFR during DES-stenting in patients with multivessel disease is superior to current angiography guided treatment. It improves outcome of PCI significantly It supports the evolving paradigm of “Functionally Complete Revascularization”, i.e. stenting of ischemic lesions and medical treatment of non-ischemic ones.,FAME study: CONCLUSIONS,Safety of DES Revascularization: CABG or PCITreatment for bifurcation: sample is better?Fractional flow-reserve for guiding PCI in multi-vessel diseaseNew generation of DES,Drug-eluting Stents 2008,Endeavor,Phosphorylcholine,Zotarolimus,Driver,Drug,Polymer,Xience V*,VDF + HFP copolymer,Everolimus,Vision,*AKA Promus,Stent,SPIRIT II + III: Cardiac Death or MI,0,2,4,6,8,10,0,3,6,9,12,15,18,21,24,Cardiac Death or MI (%),Months,Stone GW,SPIRIT II + III: All Death or MI,0,2,4,6,8,10,0,3,6,9,12,15,18,21,24,All Death or MI (%),Months,Stone GW,SPIRIT II + III: Ischemic MACE,Stone GW,SPIRIT II + III: Ischemic TVF,Ischemic TVF = Cardiac death, MI, or ischemic TVR,Stone GW,SPIRIT II + III: All TLR,All TLR = Ischemic TLR + non ischemic TLR,Stone GW,Zotarolimus-Eluting Stent:Analysis of Six Clinical Trials,Kandzari D,Euro-PCR2009,Zotarolimus-Eluting Stent:Analysis of Six Clinical Trials,Kandzari D,Euro-PCR2009,Zotarolimus-Eluting Stent:Analysis of Six Clinical Trials,Kandzari D,Euro-PCR2009,NEVO RES-ELUTION 1 Trial,Spaulding C, Euro-PCR 2009,NEVO RES-ELUTION 1 Trial,Spaulding C, Euro-PCR 2009,NEVO RES-ELUTION 1 Trial,Spaulding C, Euro-PCR 2009,NEVO RES-ELUTION 1 Trial,Spaulding C, Euro-PCR 2009,ABSORB,The goal of this trial was to evaluate the use of a bioabsorbable drug-eluting stent (DES) platform a